News／Press Release

​Jan.11,2022
Selected for the “Jury's Special Award” at the Japan Healthcare Venture Summit 2021 (JHVS2021), which is given to those who have a particularly high possibility of practical application and potential of seeds.
The exhibitor pitch was held by the Ministry of Health, Labor and Welfare on 13-15 October 2021.(Open Link. Japanese release only)

​Sep.10,2021
Exhibited "JAPAN HEALTHCARE VENTURE SUMMIT 2021" on 13-15 October 2021.

​Aug.17,2021
Initiation of the phase 1, First-in-Human, study of therapy with the oligonucleotide drug “TAKC-02” for the treatment of Steroid-resistant Severe Asthma.(Open Link)

​Jun.07,2021
Seminar/Event 
The Announcement of the 6th Annual Meeting of the Nucleic Acids Therapeutics Society of Japan. Title: “TAKC-02, an antisense oligonucleotide targeting mRNA encoding MEX3B, improves steroid-insensitive airway inflammation “  Date/Time 6/29, 16:30-16:45.(Open Link)

​Mar.29,2021
Nippon Shokubai Co., Ltd. has released a press release regarding the Completion of GMP Manufacturing for Oligonucleotide API. (Open Link)​